Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 943

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 943
---
 | ​ | ​ | As ofSeptember 30,2024 |   |       |   | ​ | ​ | As ofDecember 31,2023 |   |       |   | ​ |
|:------------------------------------------------|:--|:--|:-----------------------|:--|------:|:--|:--|:--|:----------------------|:--|------:|:--|:--|
| Prepaid research and development expenses       | ​ | ​ | ​                      | $ | 1,212 | ​ | ​ | ​ | ​                     | $ | 3,203 | ​ | ​ |
| Other prepaid expenses                          | ​ | ​ | ​                      | ​ |    53 | ​ | ​ | ​ | ​                     | ​ |    36 | ​ | ​ |
| Total prepaid expenses and other current assets | ​ | ​ | ​                      | $ | 1,265 | ​ | ​ | ​ | ​                     | $ | 3,239 | ​ | ​ |

5. Intangible Assets Intangible assets consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

| ​                              | ​ | ​ | As ofSeptember 30,2024 |   |      |   | ​ | ​ | As ofDecember 31,2023 |   |      |   | ​ |
|:-------------------------------|:--|:--|:-----------------------|:--|-----:|:--|:--|:--|:----------------------|:--|-----:|:--|:--|
| Licensed patent rights         | ​ | ​ | ​                      | $ |  826 | ​ | ​ | ​ | ​                     | $ |  826 | ​ | ​ |
| Less: accumulated amortization | ​ | ​ | ​                      | ​ | -425 | ​ | ​ | ​ | ​                     | ​ | -378 | ​ | ​ |
| Total intangible assets, net   | ​ | ​ | ​                      | $ |  401 | ​ | ​ | ​ | ​                     | $ |  448 | ​ | ​ |

As of September 30, 2024, the expected remaining amortization expense is as follows (in thousands):

| Year Ended December 31, 
 Remainder of 2024       | ​ 
 ​ | ​ 
 ​ | Amount 
 ​      |   |  16 | ​ | ​ 
 ​